Health Care

CEO sells 3,832 shares of biotech firm just before Q‑1 earnings—signals possible valuation concerns, liquidity needs and shifting payer dynamics in the evolving healthcare sector.

MeiraGTx insider sales reveal a 16% stake drop, hinting at possible confidence shifts amid volatile stock prices.

Roivant insider trading shows routine vesting, not distress—insider holdings stay above 120k shares, reinforcing long‑term confidence amid a robust oncology pipeline.

Denali Therapeutics’ insider buying signals long‑term confidence, while a home‑based AVLAYAH partnership boosts cash flow and positions the company for rare‑disease growth.

Insider buys 670 shares of Roivant Sciences as FDA Breakthrough approval sparks confidence in oncology and dermatology pipeline—watch for future price moves.

CEO Andrew Goldberg’s massive RSU and option purchases at Achieve Life Sciences reveal insider confidence, hinting at future clinical milestones and a potential upside for investors.

Belite Bio insider sales show disciplined trading, minimal dilution and steady confidence in its metabolic‑disease pipeline—why investors should stay focused on the company’s growth prospects.

Plus Therapeutics insider moves: CFO buys, CEO sells; static hold by the development chief. Discover what the next clinical data release could mean for stock volatility and investor confidence.

Inside Nuvation Bio: insider trades reveal confidence as robust ROS1, IDH1 and DDC pipelines hit breakthrough milestones and safety targets, poised for 2026 FDA approvals.

Malik Fady Ibraham’s latest 3,500‑share purchase at $65.80 signals strong insider confidence in Cytokinetics’ cardiac myosin pipeline, highlighting strategic talent hires and upcoming clinical milestones that could lift the biotech’s negative‑valuat…